Targeting PADI1 for Drug Development (G29943)

Target Name: PADI1

NCBI ID: G29943

PADI1

Targeting PADI1 for Drug Development

PADI1 (Peptidylarginine Deiminase I) is a protein that is expressed in various tissues throughout the body, including the brain, heart, kidneys, and intestinal tract. It is a member of the enzyme family 1 (also known as the aryl hydrocarbon receptor-associated gene family), which includes proteins that are involved in the detoxification of aryl hydrocarbons (AHAs) found in the environment and in the body.

PADI1 is primarily known for its role in the detoxification of 1,2-diaminobutyric acid (DABA), which is a toxic compound that can cause a wide range of health problems if ingested in high concentrations. DABA is a metabolite that is formed when certain foods, such as red meat, are cooked at high temperatures, and it has been linked to a number of diseases, including cancer, neurodegenerative disorders, and cardiovascular disease.

PADI1 is a key enzyme involved in the detoxification of DABA, and it has been shown to play a crucial role in protecting against the toxic effects of DABA. Studies have shown that mice that are genetically modified to lack PADI1 have a significantly increased risk of developing neurodegenerative symptoms, suggesting that this protein may be important for the health of the brain.

In addition to its role in the detoxification of DABA, PADI1 is also involved in the regulation of a number of other molecules in the body. For example, it has been shown to play a role in the regulation of blood pressure, and it has been shown to interact with a number of signaling pathways that are involved in cancer growth and development.

Given the potential role of PADI1 in the detoxification of DABA and its involvement in the regulation of other molecules, it is a promising target for drug development. Researchers have been exploring the use of drugs that can modulate PADI1 activity in order to treat a wide range of diseases, including neurodegenerative disorders, cancer, and cardiovascular disease.

One approach to targeting PADI1 is to use drugs that can inhibit the activity of PADI1. These drugs, known as PADI1 inhibitors, can be used to treat a variety of different conditions, including neurodegenerative disorders, cancer, and cardiovascular disease. For example, a class of drugs called inhibitors of PADI1 have been shown to be effective in treating neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

Another approach to targeting PADI1 is to use drugs that can modulate its expression. This is done by using drugs or other molecules that can interact with PADI1 and alter its levels in the body. For example, researchers have been shown to be able to use drugs to induce PADI1 expression in certain tissues, which could potentially be used to treat a variety of different conditions.

Overall, PADI1 is a protein that has the potential to be a drug target or biomarker for a wide range of diseases. Its role in the detoxification of DABA and its involvement in the regulation of other molecules make it an attractive target for drug development, and the use of drugs that can inhibit or modulate PADI1 activity could lead to the development of new treatments for a variety of diseases.

Protein Name: Peptidyl Arginine Deiminase 1

Functions: Catalyzes the deimination of arginine residues of proteins

The "PADI1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PADI1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets